

Original Article

Levels of vasopressin in children undergoing cardiopulmonary bypass*

Wynne E. Morrison,¹ Shari Simone,² Dyana Conway,² Jamie Tumulty,² Cynthia Johnson,² Marcelo Cardarelli³

¹Department of Anesthesia and Critical Care, The Children's Hospital of Philadelphia & University of Pennsylvania, Philadelphia, Pennsylvania; ²University of Maryland Hospital for Children, Baltimore, Maryland; ³Division of Cardiovascular Surgery, University of Maryland School of Medicine, Baltimore, Maryland, United States of America

Abstract Objectives: It is accepted treatment to give vasopressin to adults in postcardiotomy shock, but such use in children is controversial. Cardiopulmonary bypass is presumed to attenuate the normal endogenous vasopressin response to shock. We hypothesized that levels of vasopressin in children are altered by bypass, and that children having low endogenous levels perioperatively are more likely to develop hypotension, or require vasopressors. **Methods:** Serial levels of vasopressin were assessed prospectively in children undergoing bypass at a single center. **Results:** Of 61 eligible patients, we enrolled 39 (63%). Their median age was 5 months. The mean level of vasopressin prior to bypass was 18.6 picograms per millilitre, with an interquartile range from 2.6 to 11.4. Levels of vasopressin peaked during bypass at 87.1, this being highly significant compared to baseline ($p < 0.00005$), remained high for 12 hours at a mean of 73.5, again significantly different from baseline ($p = 0.002$), were falling at 24 hours, with a mean of 28.1 ($p = 0.04$), and had returned to baseline by 48 hours, when the mean was 7.4 ($p = 0.3$). Age, gender, and the category for surgical risk had no influence on the levels of vasopressin. There was no statistically significant relationship between the measured levels and hypotension or the requirement for vasopressors, although a few persistently hypotensive patients had high levels subsequent to bypass. Higher levels correlated with higher levels of sodium in the serum ($r_s = 0.37$, $p < 0.00005$), higher osmolality ($r_s = 0.37$, $p < 0.00005$), and positive fluid balance ($r_s = 0.23$, $p < 0.008$). Preoperative use of inhibitors of angiotensin converting enzyme, preoperative congestive cardiac failure, and longer periods of bypass predicted higher levels during the first eight postoperative hours. **Conclusions:** Children do not have deficient endogenous levels of vasopressin following bypass, and lower levels are not associated with hypotension. Any therapeutic efficacy of infusion of vasopressin for post-cardiotomy shock in children is likely due to reasons other than physiologic replacement.

Keywords: neurohormonal axis; congenital heart surgery; post-cardiotomy shock

ARGININE VASOPRESSIN IS A NONAPEPTIDE HORMONE synthesized in the hypothalamus and stored in the posterior pituitary gland.^{1,2} Its predominant

effects are mediated by so-called V1, vascular tone, and V2, renal water retention, receptors. It also has complex interactions with other hormonal systems via V3 receptors in the pituitary.^{2,3} Its most important role in healthy, euvoletic individuals is maintaining the balance of water rather than vascular tone, and infusion of vasopressin in healthy subjects does not lead to hypertension.¹

Exogenous vasopressin has increasingly been used as a therapeutic agent for various forms of vasodilatory shock, including shock following sepsis and cardiac surgery.^{4–7} Its therapeutic effect is felt

*This manuscript was presented at the Inaugural Meeting of The World Society for Pediatric and Congenital Heart Surgery in Washington DC, United States of America, May 3 and 4, 2007

Correspondence to: Wynne E. Morrison, MD, Assistant Professor, Department of Anesthesiology and Critical Care, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, 34th Street & Civic Center Blvd, Room 7C26, Philadelphia, PA 19104, United States of America. Tel: +267 426 0296; Fax: +215 590 4327; E-mail: morrisonw@email.chop.edu

Accepted for publication 5 September 2007

to be secondary to correction of a vasopressin-deficient state.⁸ There are few studies on whether assumptions regarding levels of vasopressin and post-cardiotomy vasodilatory shock are true in children. Because of this, we designed this prospective study to examine the hypotheses, first, that levels of vasopressin in children are affected by cardiopulmonary bypass; second, that children with evidence of haemodynamic instability are more likely to have inappropriately low circulating levels of vasopressin following bypass; and third, that preoperative use of inhibitors of angiotensin converting enzyme or congestive cardiac failure may affect the vasopressin or haemodynamic response to bypass, as has been shown in adults.

Materials and methods

This prospective study was conducted in a tertiary-care paediatric intensive care unit of a University hospital from November, 2004, to May, 2006. The institutional review board approved the study and signed informed consent was obtained from every parent/guardian.

Eligible patients

We considered all children under the age of 18 years undergoing cardiac surgery with cardiopulmonary bypass to be eligible. We excluded patients if bypass was not planned, if there was not an English or Spanish speaking parent or guardian, and if informed consent was not given.

Procedures

For each patient, approximately 2 millilitres of whole blood was drawn to measure a level of vasopressin immediately prior to bypass, during bypass, at the end of bypass while in the operating room, on admission to the paediatric intensive care unit, and at 4, 8, 12, 24 and 48 hours after admission to the intensive care unit. Blood was drawn only from indwelling arterial or central venous catheters, or when other samples were required by peripheral venepuncture in the routine care of the patient. No venepunctures were performed solely for the purpose of the study.

Whole blood specimens were collected in Becton Dickinson K2 EDTA tubes. Specimens were packaged and sent to the Specialty Outreach Laboratory immediately upon collection. Specimens were spun down using centrifuge at 2 to 8 degrees centigrade at 2000 gravities for 15 minutes, plasma separated from the cells and placed in a polystyrene tube and frozen at less than 20 degrees centigrade. Specimens were then sent and processed at the Specialty Laboratories in Valencia, California. Serum

was analyzed using a Buhlmann double antibody radioimmunoassay kit designed for the quantitative *in vitro* diagnostic direct measurement of vasopressin in EDTA plasma.

Data collection

Demographic and clinical information, including age, weight, gender, cardiac lesion, preoperative medications, echocardiographic and cardiac catheterization results, were recorded for each patient. The periods of cardiopulmonary bypass, cross clamping, deep hypothermic cardiac arrest, and modified ultrafiltration, along with the anaesthetics used, the surgery performed, and the postoperative echocardiographic results obtained, were also recorded. In addition, we recorded the length of stay in the intensive care unit and hospital, the number of days when vasopressors were used, the number of days of mechanical ventilation, the Pediatric Risk of Mortality III Score,⁹ and the disposition at discharge. Serum chemistries, coagulation panels, complete blood counts, and blood gases as part of routine patient care were recorded at the time samples were drawn. In addition, vital signs and fluid balance were recorded.

We calculated a vasopressor score from the doses of continuous infusions employed (Dopamine \times 1 + Dobutamine \times 1 + Epinephrine \times 100 + Norepinephrine \times 100).¹⁰ Hypotension was defined as systolic blood pressure less than the 5th percentile for age based on values used for recent sepsis guidelines.¹¹ Serum osmolality was calculated as (serum sodium \times 2) + (Blood Urea Nitrogen/2.8) + (Glucose/18). Patients were defined as having preoperative congestive cardiac failure if they were treated with digoxin, diuretics, inhibitors of angiotensin converting enzyme, or milrinone preoperatively, or if they had congestive cardiac failure listed as a diagnosis in their list of problems.

Statistical analysis

We anticipated that a study enrolling approximately 36 patients would give us 85% power to detect a difference of 7 picograms per millilitre in levels of vasopressin compared to baseline, with a two-tailed alpha of 0.05, assuming a standard deviation in levels of vasopressin of 8 picograms per millilitre.¹²

Serial levels were compared to baseline using paired t tests. Levels were log-transformed prior to t tests or analysis of variance in order to approximate a normal distribution. The p values are presented as actual values rather than being adjusted for multiple comparisons. Spearman's correlation was used to correlate levels of variance with other continuous

variables, and *t* tests or analysis of variance were used to compare levels between groups. Significant correlations were confirmed using linear regression with adjustment for multiple within-subject measurements. Paired *t* tests were used to compare serial levels to baseline. Fisher's exact test was used for comparisons between categorical variables. Receiver-operating characteristic analysis was used to evaluate the level of vasopressin as a predictor of hypotension. Values are expressed as mean and standard deviation unless otherwise stated. All analyses were performed with Stata 8.0 (Stata Corporation, College Station, Texas).

Results

We identified 63 eligible subjects. Of these, 47 agreed to participate in the study. Data were obtained on 39 patients, described in Table 1. The 8 remaining patients were excluded because key samples were either not drawn or misprocessed in the laboratory. During the course of the study, 3 patients were treated with infusions of vasopressin, 2 of whom died. Levels were higher during treatment with vasopressin than at other times, at 393 plus or minus 258 versus 51 plus or minus 114 ($p < 0.0005$). Values obtained during treatment with vasopressin, therefore, are not included in the remainder of the analyses.

Table 2 shows the serial levels of vasopressin before, during, and after cardiopulmonary bypass. Levels rose during bypass, slowly fell over the following 24 hours, and returned to baseline by 48 hours. Patient age, gender, and the category for surgical risk did not correlate with levels of vasopressin. Longer duration of bypass predicted a higher level, with a 2.5 picogram per millilitre (95% confidence intervals from 1.4 to 3.6) increase in levels immediately after bypass for each additional minute of bypass. This relationship was no longer apparent by 12 hours after bypass.

Levels did not differ at baseline between patients treated with inhibitors of angiotensin converting enzyme preoperatively and those who were not, at 11 versus 20 picograms per millilitre, $p = 0.65$, with 95% confidence intervals for the difference from -33 to 51 picograms per millilitre, although levels after bypass were higher in those treated with inhibitors of angiotensin converting enzyme preoperatively, at 137 plus or minus 198 versus 37 plus or minus 103 picograms per millilitre ($p < 0.00005$), with significant differences noted at admission to the paediatric intensive care unit, and after 4 hours and 8 hours. Preoperative use of inhibitors of angiotensin converting enzyme did not predict the requirement for infusion of vasopressin

Table 1. Patient characteristics ($n = 39$). Values are expressed as number (percent) or median (range).

Male	20 (51%)
Age (years)	0.4 (0.02–10)
Weight (kilograms)	8.2 (1.5–32)
Surgical risk category ¹⁴	
Level 2	25 (64%)
Level 3	8 (21%)
Level 4	6 (15%)
Preoperative congestive cardiac failure	15 (38%)
Preoperative angiotensin converting enzyme inhibitor use	5 (13%)
Pediatric Risk of Mortality III score	9 (0–24)
Procedures performed, <i>n</i> (%):	
VSD +/- ASD repair	13 (33%)
Tetralogy of Fallot repair/redo	7 (18%)
Fontan procedure	4 (10%)
Arterial switch procedure	4 (10%)
Bidirectional cavopulmonary shunt	3 (8%)
Mitral valve replacement/repair	2 (5%)
Atrioventricular septal defect repair	2 (5%)
Interrupted aortic arch/VSD	1 (3%)
Subaortic shelf resection	1 (3%)
Mustard/pulmonary valvectomy	1 (3%)
PAPVR repair	1 (3%)
Inotropes used, patients (%):	
Dopamine	24 (62%)
Epinephrine	12 (31%)
Milrinone	25 (64%)
Length of stay (days)	8 (1–148)
30-day mortality	2 (5%)
Treated with vasopressin	3 (8%)

VSD = Ventricular septal defect, ASD = Atrial Septal Defect, PAPVR = Partial anomalous pulmonary venous return.

Table 2. Mean levels of vasopressin, in picograms per millilitre, at each time point. *p* values represent comparisons with pre-bypass levels. Measurements on therapeutic vasopressin excluded.

Time	Mean (Standard Deviation)	Interquartile range	
Pre-bypass	18.6 (42)	2.6–11.4	
During bypass	87.1 (87)	29.6–107	$p < 0.00005$
Post-bypass	88.1 (216)	7.6–23	$p = 0.0008$
4 hour	44.9 (61)	9.4–58.7	$p = 0.0001$
8 hour	54.9 (138)	10.2–37.2	$p = 0.003$
12 hour	43.6 (97)	6–34.5	$p = 0.002$
24 hour	17.8 (24)	4.4–20.3	$p = 0.036$
48 hour	7.3 (6)	3–12.1	$p = 0.3$

during hospitalization ($p = 0.3$), or the development of hypotension ($p = 0.28$).

Levels of vasopressin at baseline did not differ between patients with or without preoperative congestive cardiac failure, at 13.9 versus 22 picograms per millilitre, $p = 0.37$, with 95% confidence intervals for difference from -22 to 38 picograms per millilitre. Levels after bypass, however, were higher in patients with preoperative congestive cardiac failure, at 73

plus or minus 148 versus 35 plus or minus 104, $p = 0.0001$, with significant time points at admission to the paediatric intensive care unit and after 4 hours. Patients with preoperative congestive cardiac failure were not significantly more likely to require infusions of vasopressin, 13% versus 3%, ($p = 0.54$), or to become hypotensive ($p = 0.5$).

Measurements of systolic blood pressure taken during the study were under the 5th percentile for age 22% of the time. Of the patients, 24 (62%) thereby met this definition for hypotension for at least one measurement during the study. Only 4 patients (10%) exhibited persistent hypotension over more than two time points. There was no correlation of levels of vasopressin with either the vasopressor score ($p = 0.4$) or the presence of hypotension ($p = 0.55$), although patients with persistent hypotension did have higher levels immediately after bypass, at 422 versus 42 picograms per millilitre, ($p = 0.008$). The differences at other time points did not reach statistical significance.

Levels measured while patients were being treated with vasopressin were excluded from the analysis, but we did examine the level immediately prior to the decision to begin vasopressin in each patient to determine if it was unusually low. Levels immediately prior to beginning infusions were still above baseline, ranging from 59 to 809 picograms per millilitre, and when compared to all other levels obtained were higher, at a mean of 347 picograms per millilitre versus 59 picograms per millilitre ($p = 0.003$). Of the patients treated with vasopressin, 2 were in the persistently hypotensive group. In addition, the level of vasopressin did not correlate with central venous pressure.

Receiver-operative characteristic analysis (Fig. 1) showed that the level of vasopressin was a poor predictor of hypotension, with an area under the curve of 0.65 and no cutoff point with an adequate sensitivity and specificity. "Deficient" levels, less than 10 picograms per millilitre,¹³ during hypotension were seen in only 4 patients immediately after bypass, and in only 2 patients at 48 hours. Only one of these patients, with a deficient level at 48 hours, was in the group with persistent hypotension. All other time points showed no inappropriately low levels in hypotensive patients.

The category for surgical risk as defined in the RACHS-1 consensus statement¹⁴ did not significantly influence levels of vasopressin ($p = 0.12$). Patients who died had a trend towards having higher postoperative levels compared to patients who survived, at 106 plus or minus 235 versus 47 plus or minus 114 picograms per millilitre ($p = 0.056$). Pediatric Risk of Mortality III score did not correlate with higher postoperative levels ($p = 0.4$).




Figure 1.

Receiver operating characteristic curve using the level of vasopressin as a predictor of hypotension. Area Under the Curve demonstrates that the level would be lower in patients with hypotension versus those without only 65% of the time.




Figure 2.

Levels of vasopressin level plotted against sodium in the serum, Spearman's rho = 0.37, $p < 0.0005$. Values obtained during treatment with vasopressin excluded.

Higher levels of vasopressin correlated with both higher levels of sodium in the serum (Spearman's rho = 0.37, $p < 0.0005$, Fig. 2) and higher calculated serum osmolality (Spearman's rho = 0.37, $p < 0.0005$, Fig. 3). The association remained significant ($p < 0.0005$ for sodium and $p = 0.003$ for osmolality) on regression analysis adjusted for multiple within-subject measurements. Higher levels of vasopressin also correlated weakly with a positive fluid balance (Spearman's rho = 0.23, $p = 0.008$).

Discussion

The vasopressor and water-balance effects of pituitary extracts were first described over 100 years ago, and vasopressin was first isolated and synthesized in




Figure 3.

Levels of vasopressin plotted against calculated serum osmolality, Spearman's $\rho = 0.37$, $p < 0.0005$. Values obtained during treatment with vasopressin excluded. Outliers with vasopressin level greater than 400 excluded from graph for clarity, but were included in analysis.

the early 1950s, work which quickly led to a Nobel prize.¹⁵ Cardiac surgery and atrial stretch were recognized to affect levels of vasopressin in humans and animals over 40 years ago.^{16,17}

More recently, attention has focused on levels of vasopressin and treatment with exogenous infusions of the agent in states of vasodilatory shock, such as septic and post-cardiotomy shock.^{3–6,16–21} It has been hypothesized that patients in these forms of vasodilatory shock have a relative deficiency of vasopressin, which can be corrected by replacement. Vasodilatory shock after cardiac surgery may be more common in adults with preexisting congestive cardiac failure or use of inhibitors of angiotensin converting enzyme.⁵

Relatively few studies have examined levels of vasopressin in children following cardiac surgery. Kindelan, *et al.*¹² showed minimal changes from preoperative levels in 65 children, but did not assess levels until 24 hours postoperatively. Another series of 9 children¹⁸ showed that mean levels rose to 153 picograms per millilitre following bypass, and were higher than normal for 12 to 24 hours. Another small series¹⁹ reported on 11 children treated with vasopressin as a rescue therapy postoperatively. In 3 of these children, levels ranged from 1.9 to 52.4, felt to be inappropriately low given their degree of hypotension.

We have now shown that cardiopulmonary bypass affects endogenous levels in children. In our cohort, the levels rose during and immediately after bypass, then fell to normal within 24 to 48 hours. Surprisingly, we were unable to demonstrate any relationship between low levels and the requirement for vasopressors or hypotension,

although others have shown no correlation with haemodynamic variables.^{13,20} Similar to a recent study of serial levels in children with sepsis,²¹ very few of our patients seemed ever to become vasopressin “deficient”. In fact, persistently hypotensive patients seemed to have higher levels immediately after bypass. It is possible that children are not as likely to deplete their stores of vasopressin as adults, which could potentially explain the lower incidence of vasodilatory shock in children.²²

Longer cardiopulmonary bypass time did correlate with higher levels, as did preoperative use of inhibitors of angiotensin converting enzyme and congestive cardiac failure, at least at some time points. In contrast to adults, however, use of inhibitors of angiotensin converting enzyme and preoperative congestive cardiac failure did not lead to a compromised postoperative haemodynamic state. The correlation of higher levels of sodium in the serum, and calculated serum osmolality, with higher levels of vasopressin presumably reflects the powerful osmolar stimulus to secretion of vasopressin, although we are unable to demonstrate the direction of causality in these data.

There are limitations to our study. Standards for age-appropriate definitions of hypotension are not as readily available in children as they are in adults, as illustrated by recent challenges in finding appropriate definitions for guidelines for the treatment of septic shock.¹¹ The difficulty in finding appropriate percentiles is reflected in the fact that two of the patients in our series were “hypotensive” by the criteria used preoperatively. We also did not include findings from physical examination in our data collection that could be used to differentiate vasodilatory shock from other causes of hypotension, due to the difficulty in establishing objective criteria. None of our patients had pulmonary arterial catheters in place for measurement of cardiac output and systemic vascular resistance.

There is also no standard definition of vasopressin “deficiency” or what level represents an inappropriate response to hypotension, with cutoffs from 3.6 to 20 picograms per millilitre having been used in the literature.^{3,13,23} Receiver operating characteristic analysis using our data did not demonstrate an appropriate cutoff point for associating a level of vasopressin with hypotension.

The variability in levels of vasopressin in our data was much greater than that shown in other studies.¹² This may have decreased the power of the study to show significant differences, but the change in levels from baseline over time, our primary outcome, was dramatic enough that the difference was significant despite the wide variability. It is possible that our study was not adequately powered to assess some of

our secondary outcomes. For instance, there were few patients enrolled with preoperative congestive cardiac failure or preoperative use of inhibitors of angiotensin converting enzyme, resulting in the wide confidence intervals shown.

It is possible that massive transfusion of stored blood during bypass affected our measured levels, although this could not explain the sustained rise in levels as a vasopressin half-life of approximately 11 minutes^{2,7,21} should have allowed levels to fall more rapidly. We checked the level from the prime used in one cardiopulmonary bypass circuit before placing the patient on bypass, and the level was not elevated at 7.9 picograms per millilitre.

We can conclude from our study that cardiopulmonary bypass in children leads to elevated levels of vasopressin compared to preoperative values. Additional analysis showed that longer duration of cardiopulmonary bypass was associated with higher postoperative levels, and that higher levels were seen in patients with preoperative congestive cardiac failure, or those using inhibitors of angiotensin converting enzyme. Higher levels also correlated with higher levels of sodium in the serum, and calculated osmolality, as well as weakly with positive fluid balance. We found no evidence for correlation of post-cardiotomy hypotension with a vasopressin-deficient state in children. Exogenous vasopressin may still have an appropriate therapeutic role in children after cardiac surgery, but it cannot be presumed that its effect is mediated by physiologic replacement. Multi-centric trials on the therapeutic use of vasopressin are currently underway in adults with cardiac arrest, septic shock and hemorrhagic shock.^{1,15} Further studies are indicated in children to determine how their physiologic and therapeutic response differs.

Acknowledgements

We thank the Rafael Nieves Foundation for their generous support of this study. We also could not have performed it without the assistance of Dr Anne Savarese and Dr Monique Bellefleur in the Department of Anesthesiology, who coordinated all the intraoperative measurements of vasopressin.

Work supported by a grant from the Rafael Nieves Foundation.

References

- Vincent JL. Vasopressin in hypotensive and shock states. *Crit Care Clin* 2006; 22: 187–197.
- Treschan TA, Peters J. The vasopressin system: physiology and clinical strategies. *Anesthesiology* 2006; 105: 599–612.
- Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D. Circulating vasopressin levels in septic shock. *Crit Care Med* 2003; 31: 1752–1758.
- Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. *N Engl J Med* 2001; 345: 588–595.
- Argenziano M, Chen JM, Choudhri AF, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. *J Thorac Cardiovasc Surg* 1998; 116: 973–980.
- Argenziano M, Choudhri AF, Oz MC, Rose EA, Smith CR, Landry DW. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. *Circulation* 1997; 96: 286–290.
- Barrett LK, Singer M, Clapp LH. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. *Crit Care Med* 2007; 35: 33–40.
- Landry DW, Oliver JA. Vasopressin and relativity: on the matter of deficiency and sensitivity. *Crit Care Med* 2006; 34: 1275–1277.
- Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality score. *Crit Care Med* 1996; 24: 743–752.
- Zuppa AF, Nadkarni V, Davis L, et al. The effect of a thyroid hormone infusion on vasopressor support in critically ill children with cessation of neurologic function. *Crit Care Med* 2004; 32: 2318–2322.
- Goldstein B, Giroir B, Randolph A. Values for systolic blood pressure: authors reply. *Pediatr Crit Care Med* 2005; 6: 500.
- Kindelan A, Navero J, De la Rosa I, et al. Relationship between hemodynamic changes and blood hormone concentrations after cardiac surgery in children with congenital heart disease. *Crit Care Med* 1994; 22: 1754–1761.
- Jochberger S, Mayr VD, Luckner G, et al. Serum vasopressin concentrations in critically ill patients. *Crit Care Med* 2006; 34: 293–299.
- Jenkins KJ, Gauvreau K, Newburger JW, Spray TL, Moller JH, Iezzoni LI. Consensus-based method for risk adjustment for surgery for congenital heart disease. *J Thorac Cardiovasc Surg* 2002; 123: 110–118.
- Dunser MW, Lindner KH, Wenzel V. A century of arginine vasopressin research leading to new therapeutic strategies. *Anesthesiology* 2006; 105: 444–445.
- Shu'ayb WA, Moran WH, Zimmerman B. Studies of the mechanism of antidiuretic hormone secretion and the post-commisurotomy dilutional syndrome. *Ann Surg* 1965; 162: 690–699.
- Richardson RL, Giles H, Pate JW. Antidiuretic hormone secretion: its relation to cardiac surgery and injury. *J Tenn Med Assoc* 1969; 62: 1126–1128.
- Ationu A, Singer DR, Smith A, Elliott M, Burch M, Carter ND. Studies of cardiopulmonary bypass in children: implications for the regulation of brain natriuretic peptide. *Cardiovasc Res* 1993; 27: 1538–1541.
- Rosenzweig EB, Starc TJ, Chen JM, et al. Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery. *Circulation* 1999; 100 (Suppl): II182–II186.
- Boldt J, Menges T, Kuhn D, Diridis C, Hempelmann G. Alterations in circulating vasoactive substances in the critically ill—a comparison between survivors and non-survivors. *Intensive Care Med* 1995; 21: 218–225.
- Lodha R, Vivekanandhan S, Sarthi M, Kabra SK. Serial circulating vasopressin levels in children with septic shock. *Pediatr Crit Care Med* 2006; 7: 220–224.
- Killinger JS, Hsu DT, Hardart GE. The incidence of vasodilatory shock (VDS) in children after cardiopulmonary bypass (CPB). *Crit Care Med* 2006; 34: A61.
- Albright TN, Zimmerman MA, Selzman CH. Vasopressin in the cardiac surgery intensive care unit. *Am J Crit Care* 2002; 11: 326–330.